Evaluate：2024年全球生物制药行业展望报告：增长驱动力分析（英文版）（29页）.pdf

《Evaluate：2024年全球生物制药行业展望报告：增长驱动力分析（英文版）（29页）.pdf》由会员分享，可在线阅读，更多相关《Evaluate：2024年全球生物制药行业展望报告：增长驱动力分析（英文版）（29页）.pdf（29页珍藏版）》请在三个皮匠报告上搜索。

1、Click here or press enter for the accessibility optimised versionWorld Preview2024:PharmasGrowth BoostClick here or press enter for the accessibility optimised versionForewordLast years Age of Uncertaintyhas given way to morepredictable realities,includingthe dominance of obesity andother big diseas

2、es,a widerrange of modalities and anIRA thats here to stay.Obesity drugs loom large over 2030 forecasts.GLP-1 agonists and relatedincretins are helping drive record overall prescription drug sales growth,propelling leaders Novo Nordisk and Eli Lilly to the top of the companyrankings and hogging the

3、lions share of the 2030 product top-ten.Ascompetition ramps up,more potent compounds,combinations and oralformulations will likely support metabolic diseases dominance into the nextdecade and beyond.Immuno-inflammation and oncology also make 2030s top ten.SanofisDupixent and AbbVies Skyrizi will be

4、the biggest non-obesity drugs.Resurgent CNS and respiratory are both prominent among most valuablepipeline candidates,as industrys red-hot innovation engine drivesadvances across the board.New modalities and technologies continue toopen up novel targets and targeting mechanisms:antibody drugconjugat

5、es(ADCs),multi-specific antibodies,RNA-based therapies,gene/cell therapies and radiopharmaceuticals are all expected to grow steeply to2030.Big Pharmas appetite for Big Drugs for Big Diseases reflects ongoingpatent expiry challenges,expected to spike the likes of Merck,J&J andBristol Myers Squib

6、b this decade.Patent expiries are a feature of thelandscape,just like the M&A that can help address them.Pharmaacquisitions reached a healthy$124 billion in 2023 and look similarly strongso far in 2024 welcome news for biotechs,given stubbornly lacklustrepublic markets.Pharma cash-piles and expi